Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoladex plus salvage radiotherapy versus salvage radiotherapy alone after prostatectomy
2005-005165-11Phase 3Terminated
- Sponsor
- Unicancer
- Start
- Apr 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Unicancer. Primary endpoints: Efficacy and Progression-free survival. Started Apr 2006; status: terminated.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005165-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005165-11.